Biogen Idec (BIIB)
Add to Watchlists Create an Alert
235.24
+2.62 +1.13%
NASDAQ
May 24, 8:00PM
BATS Real time
Currency in USD
Biogen Idec Debt to Equity Ratio:
0.1247 for March 31, 2013Biogen Idec Historical Debt to Equity Ratio Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 0.1247 |
| Dec. 31, 2012 | 0.1639 |
| Sept. 30, 2012 | 0.1669 |
| June 30, 2012 | 0.1746 |
| March 31, 2012 | 0.1712 |
| Dec. 31, 2011 | 0.1656 |
| Sept. 30, 2011 | 0.1708 |
| June 30, 2011 | 0.1999 |
| March 31, 2011 | 0.2142 |
| Dec. 31, 2010 | 0.223 |
| Sept. 30, 2010 | 0.2147 |
| June 30, 2010 | 0.2088 |
| March 31, 2010 | 0.1854 |
| Dec. 31, 2009 | 0.1768 |
| Sept. 30, 2009 | 0.1678 |
| June 30, 2009 | 0.1771 |
| March 31, 2009 | 0.1853 |
| Dec. 31, 2008 | 0.1917 |
About Debt to Equity Ratio
Leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. A low debt to equity ratio indicates lower risk, because debt holders have less claims on the company's assets. A debt to equity ratio of 5 means that debt holders have a 5 times more claim on assets than equity holders.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
BIIB Debt to Equity Ratio Benchmarks
| Companies | |
|---|---|
| Elan | 0.8795 |
| Novartis | 0.3125 |
| Celgene Corporation | 0.5628 |
BIIB Debt to Equity Ratio Rankings
| Overall |
76th percentile 1886 of 8009 |
| Sector |
56th percentile 299 of 687 in Healthcare |
| Industry |
48th percentile 128 of 248 in Biotechnology |
BIIB Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.1247 | Mar 2013 |
| Maximum | 0.2230 | Dec 2010 |
| Average | 0.1824 |
